EICHORCondition: Home Based Standardised Adapted Physical Activity Programme · Patients Taking Oral Targeted Therapy for Metastatic Cancer · Sponsor: UNICANCER
This phase II-III study will be randomized (2:1) patients starting first-line oral targeted therapies (OTT) for metastatic cancer between an individualized supervised physical exercise programs (SPEP) by a personal coach, and recommended physical exercises via a booklet. Eligible patients will have received ≤2 lines of metastatic chemotherapy, Eastern Cooperative Oncology Group Performance status (ECOG PS) ≤2, controlled pain (visual analogue scale (VAS) \<3/10), and life expectancy ≥3 months.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| ICO Paul Papin | Angers, France | — |
| CH Annecy Genevois - site d'Annecy | Annecy, France | — |
| CHRU de Besançon | Besançon, France | — |
| Centre François Baclesse | Caen, France | — |
| CH de Cholet | Cholet, France | — |
| GHMG - Institut Daniel Hollard | Grenoble, France | — |
| CHD Vendée | La Roche-sur-Yon, France | — |
| Hospices Civils de Lyon - Hôpital Louis Pradel | Lyon, France | — |
| CHU La Timone | Marseille, France | — |
| ICO RenéGauducheau | Nantes, France | — |
| CH Nimes - Institut de Cancérologie du Gard | Nîmes, France | — |
| Institut Curie Paris | Paris, France | — |
+ 3 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03169075